Plus (PSTV) Upgraded to Buy: Here's Why

Plus Therapeutics (PSTV) has been upgraded to a Zacks Rank #2 (Buy) due to a significant 78.7% increase in the consensus EPS estimate for fiscal year 2025 over the past three months, now projecting a loss of -$0.34 per share. This upgrade, driven by positive earnings estimate revisions, suggests potential near-term stock appreciation as institutional investors adjust valuations, aligning with the Zacks Rank system's historical success in identifying stocks likely to outperform the market.

Analysis

Plus Therapeutics (PSTV) has received an upgraded Zacks Rank to #2 (Buy), primarily attributed to a significant positive shift in its earnings estimate outlook. Over the past three months, the Zacks Consensus Estimate for PSTV's fiscal year 2025 earnings per share (EPS) has improved by 78.7%, now standing at a loss of -$0.34 per share. This upward revision is considered a powerful catalyst for near-term stock price movements, as the Zacks Rank system emphasizes changes in corporate earnings potential, which often influences institutional investors to adjust their valuations and trading activity. According to the article, the Zacks Rank system has an externally-audited track record, with its top-rated stocks historically outperforming the market. However, it is crucial to note that while the FY2025 EPS estimate for this developer of cell therapies has seen a substantial positive revision, the projected -$0.34 EPS still indicates an operational loss and, importantly, represents no anticipated year-over-year change in earnings level from the previous fiscal year. The upgrade places PSTV in the top 20% of stocks covered by Zacks in terms of estimate revisions, suggesting a potentially favorable impact on its stock price in the near term based on this specific methodology.

Key Decisions for Investors

• Investors should consider the Zacks Rank #2 (Buy) for Plus Therapeutics as a signal of potential near-term upward price movement, primarily driven by the recent 78.7% positive revision in its FY2025 consensus EPS estimate.
• It is advisable to weigh the improved earnings estimate momentum, which underpins the Zacks Buy rating, against the fundamental reality that the company is still projected to report a loss of -$0.34 per share in FY2025, a level that indicates no earnings growth compared to the prior year.
• Monitor subsequent earnings estimate revisions and the company's progress towards achieving profitability, as the Zacks Rank is largely a near-term indicator responsive to such changes, and the current outlook still points to continued losses.